Data point to disparities in receipt of SBRT for prostate cancer
"The patients who received SBRT were more likely to be Caucasian. We observed that far fewer Black men were treated with SBRT in our cohort," says Michael Stencel, DO.
In this video, Michael Stencel, DO, discusses the Urology paper, “Stereotactic Body Radiation Adoption Impacts Prostate Cancer Treatment Patterns.” Stencel is a urologist with Charleston Area Medical Center in Charleston, West Virginia.
Transcription:
The study identified differences in treatment mix between SBRT and non-SBRT networks. How do you explain these differences, and what are the implications for patient outcomes?
The patients who received SBRT were more likely to be Caucasian. We observed that far fewer Black men were treated with SBRT in our cohort. And when we looked at the logarithmic regression model, the Black men were 43% less likely to receive SBRT, which I think goes in line with a little bit of what we know about prostate cancer treatment disparities, that mortality is worse for Black men in addition to stage at presentation. And so I think when we look at access to care and when we look specifically at access to SBRT, it looks like this group is at a particular disadvantage.
This transcript was edited for clarity.
Olaparib monotherapy shows benefit in HRR+ biochemically recurrent prostate cancer
August 22nd 2024“This study is a breakthrough because it is the first trial to show that a non-hormonal drug can induce durable complete remissions in recurrent prostate cancer patients with BRCA2 mutations—one of the most aggressive subtypes of this disease,” says Emmanuel S. Antonarakis, MD.
